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Abstract
The misfolding of proteins and their accumulation in extracellular tissue compartments as insoluble amyloid
or amorphous protein aggregates are a hallmark feature of many debilitating protein deposition diseases such
as Alzheimer's disease, prion diseases, and type II diabetes. The plasminogen activation system is best known
as an extracellular fibrinolytic system but was previously reported to also be capable of degrading amyloid
fibrils. Here we show that amorphous protein aggregates interact with tissue-type plasminogen activator and
plasminogen, via an exposed lysine-dependent mechanism, to efficiently generate plasmin. The insoluble
aggregate-bound plasmin is shielded from inhibition by α2-antiplasmin and degrades amorphous protein
aggregates to release smaller, soluble but relatively hydrophobic fragments of protein (plasmin-generated
protein fragments (PGPFs)) that are cytotoxic. In vitro, both endothelial and microglial cells bound and
internalized PGPFs before trafficking them to lysosomes. Clusterin and α2-macroglobulin bound to PGPFs to
significantly ameliorate their toxicity. On the basis of these findings, we hypothesize that, as part of the in vivo
extracellular proteostasis system, the plasminogen activation system may work synergistically with
extracellular chaperones to safely clear large and otherwise pathological protein aggregates from the body.
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The misfolding of proteins and their accumulation in extra-
cellular tissue compartments as insoluble amyloid or amor-
phous protein aggregates are a hallmark feature of many debil-
itating protein deposition diseases such as Alzheimer’s disease,
prion diseases, and type II diabetes. The plasminogen activation
system is best known as an extracellular fibrinolytic system but
was previously reported to also be capable of degrading amyloid
fibrils. Here we show that amorphous protein aggregates inter-
act with tissue-type plasminogen activator and plasminogen, via
an exposed lysine-dependent mechanism, to efficiently generate
plasmin. The insoluble aggregate-bound plasmin is shielded
from inhibition by 2-antiplasmin and degrades amorphous
protein aggregates to release smaller, soluble but relatively
hydrophobic fragments of protein (plasmin-generated protein
fragments (PGPFs)) that are cytotoxic. In vitro, both endothelial
and microglial cells bound and internalized PGPFs before traf-
ficking them to lysosomes. Clusterin and 2-macroglobulin
bound to PGPFs to significantly ameliorate their toxicity. On
the basis of these findings, we hypothesize that, as part of the in
vivo extracellular proteostasis system, the plasminogen activa-
tion system may work synergistically with extracellular chaper-
ones to safely clear large and otherwise pathological protein
aggregates from the body.
We previously identified a number of abundant extracellular
chaperones (ECs)4 found in body fluids that have the ability to
specifically bind to exposed regions of hydrophobicity on mis-
folded proteins to inhibit their toxicity and facilitate their safe
clearance and disposal. This is relevant to a broad variety of
serious human diseases, the protein deposition diseases, in
which pathology is associated with inappropriate misfolding,
aggregation, and deposition of extracellular proteins (e.g. Alz-
heimer’s disease, type II diabetes, prion diseases, etc.). The
clearance mechanism is thought to involve ECs forming soluble
complexes with misfolded proteins (or oligomers) and the
delivery of these to cell surface receptors for uptake and subse-
quent lysosomal degradation (1). Acting alone, however, these
systems are not capable of clearing large, insoluble extracellular
protein deposits that are associated with pathology in, for
example, systemic amyloidosis and rheumatoid arthritis. Nev-
ertheless, following successful clinical treatment, the extracel-
lular tissue deposits that characterize these diseases measurably
regress (2), implying that the body does have an effective mech-
anism(s) to clear large, insoluble protein deposits from extra-
cellular spaces. Obvious candidates for involvement in such
systems are extracellular proteases, in particular those that can
be specifically activated by protein aggregates. Conceivably,
proteases such as this could digest insoluble extracellular pro-
tein aggregates to generate smaller, soluble protein fragments
that are more amenable to clearance, potentially via the same
EC-facilitated mechanisms implicated in clearing soluble mis-
folded proteins/oligomers (as proposed in Ref. 1).
The plasminogen activation system (PAS) is a suitable can-
didate extracellular protease system that may contribute to the
degradation of insoluble extracellular protein deposits in vivo.
The PAS includes many proteolytic enzymes with functions
ranging from tumor invasion and metastasis, tissue remodeling
(3, 4), and reproduction (5) to the inflammatory response (6)
and hemostasis (7). It includes the major protease plasmin
(plm; a broad spectrum serine protease), plasminogen (plg; the
zymogen form of plm), specific mammalian plg activators,
urokinase-type plg activator, and tissue-type plg activator (tPA)
as well as plg activator inhibitors type-1 and -2 and inhibitors of
plasmin such as 2-antiplasmin (A2AP) and 2-macroglobulin
(A2M) (3, 4). Plm degrades fibrin and fibrinogen with the high-
est specificity; termed fibrinolysis, this process is important for
wound healing and hemostasis (8). When both tPA and plg bind
to fibrin, tPA cleaves plg to generate active plm, leading to dis-
solution of macromolecular fibrin clots. Interestingly, it has
been reported that plasmin digestion of fibrin yields several
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specific proteolytic fragments, including a cytotoxic “fibrin
fragment E,” which induces apoptosis in a variety of cell types
(9).
The PAS is also known to be activated by aggregated amyloid
, the peptide that forms insoluble plaques in the brains of
Alzheimer’s disease patients, and plm degrades fibrillar A
with physiologically relevant efficiency (10). Previous work sug-
gests that tPA binds to both fibrin and amyloid proteins by
recognizing cross--sheet structure (11). Cross--sheet struc-
ture may promote the interaction between tPA and plg, result-
ing in plm-mediated degradation of -sheet-rich proteins inde-
pendent of their amino acid sequence (11, 12). Other proteins
known to activate the PAS include prion protein (14), extracel-
lular matrix proteins, actin, glycated proteins, and thrombos-
pondin (4). Furthermore, several earlier reports have described
plg activation by a wide range of denatured proteins but not by
the corresponding native proteins (15–17). These denatured
proteins were not structurally characterized, but the harsh con-
ditions used to generate them (e.g. extremes of pH and temper-
ature (15, 17)) are likely to have mostly resulted in the forma-
tion of unstructured amorphous protein aggregates. Injured
cells with damaged cell membranes also release protein aggre-
gates that induce tPA-mediated plm formation, facilitating
removal of the aggregates by proteolytic degradation (12). The
aggregates examined in the latter study were shown to stain
with thiazine red R and Congo red, indicating that they were
rich in -sheet content, but were otherwise not structurally
characterized (12).
Although previous work has identified that denatured pro-
teins, but not the corresponding native proteins, can induce plg
activation to plm, there has been limited characterization of the
structural features responsible for this activity. Furthermore,
although the products of plm digestion of fibrin clots have cer-
tainly been studied (9, 18), the corresponding plm digestion
products of amorphous protein aggregates had not been exam-
ined. In the current study, we generated and biophysically char-
acterized amorphous aggregates from ovotransferrin (OVO)
and the G93A mutant of superoxide dismutase 1 (SOD) and
confirmed that they act as efficient cofactors for the PAS. We
then characterized the products of plm-mediated digestion of
the amorphous aggregates as hydrophobic and cytotoxic pro-
tein fragments (peptides) of varying size that are internalized by
cells and that are specifically bound by ECs, which inhibits their
toxicity. These results are consistent with a hypothetical model
in which the collective in vivo activities of ECs and the PAS may
help safely clear large and otherwise pathological protein aggre-
gates from the body.
Results
Generation and characterization of aggregates of SOD and
OVO
The G93A mutant of SOD and OVO were subjected to
chemical reduction (50 mM DTT for 24 h at 37 °C) or heat
(60 °C for 2 h), respectively, to induce protein aggregation. SOD
is capable of generating fibrillar aggregates under conditions
similar to those used here, but this process is often difficult
to reproduce in vitro (19). In our hands, using the method
described, recombinant SOD produced amorphous aggregates.
The generation of amorphous OVO aggregates using the con-
ditions described has been reported previously (20). When
treated in this way, the two proteins showed a time-dependent
increase in exposed hydrophobicity, detected by 4,4-bis(1-ani-
lino-8-naphthalene sulfonate) (bisANS) fluorescence, which
plateaued at later stages of the time course (Fig. 1, A and B).
Similarly, after a short lag phase, the turbidity (A360) of the
protein solutions quickly increased before also plateauing at the
later stages of the time course (Fig. 1, A and B). These results
suggest that the conditions used first induce misfolding of the
protein molecules associated with an increase in regions of
exposed hydrophobicity and then a time-dependent associa-
tion of the misfolded species to form increasingly large, light-
scattering aggregates. Thioflavin T fluorescence analyses indi-
cated that the aggregates formed did not contain significant
quantities of cross--sheet content and were therefore not
amyloid in structure (Fig. 1C). Scanning electron microscopy of
the end point aggregates indicated in both cases an amorphous
structure lacking fibrillar content (Fig. 1D).
Amorphous protein aggregates stimulate activation of plg to
plm by a lysine-dependent mechanism and protect plm from
inhibition by A2AP
Fibrin stimulated the fastest initial rate of change of plm
activity with mean values of 0.101  0.030 A405min2 (n  9).
This equated to an average -fold increase of 7.1  1.7 com-
pared with tPA/plg alone across three independent assays (Fig.
2, A and B). When also expressed as a -fold increase in initial
rate of change of plm activity compared with tPA/plg alone,
both amorphous protein aggregates gave a similar mean -fold
increase of 2.5  0.4 across three independent assays (Fig. 2, A
and B). This suggests that, analogous to fibrin, amorphous
aggregates likely co-localize tPA and plg, thereby acting as a
cofactor to increase the rate of activation of plg to plm. The
extent of plg activation was dependent on the amount of amor-
phous aggregate present; early time point samples from protein
aggregation mixtures, which contained fewer large aggregates,
elicited lower levels of plm activation (supplemental Fig. 1). The
results of related experiments confirmed that activation of the
tPA/plg system by amorphous protein aggregates is not exclu-
sive to SOD and OVO (supplemental Fig. 2). The binding of tPA
and plg to fibrin is lysine-dependent. It was previously reported
that this was also a requirement for the activation of plg by
denatured proteins (16). The lysine-like analogue tranexamic
acid (TXA) is commonly used to confirm the lysine-dependent
binding of plg to various ligands and receptors (4). We showed
that TXA significantly inhibited the ability of SOD aggregates
and fibrin (as an intra-assay cofactor control) to elicit plg acti-
vation by 47 and 64%, respectively, compared with no-TXA
controls (Fig. 2C). Similarly, TXA significantly inhibited OVO-
and fibrin-mediated plg activation by 90 and 86%, respec-
tively (Fig. 2D). These results confirm an important role for
lysine residues in the interaction between amorphous protein
aggregates and tPA/plg.
In mammalian plasma, A2AP is the main physiologic plm
inhibitor; it acts by rapidly forming a 1:1 stoichiometric com-
plex with the protease (21–23). For plm to perform its primary
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role, the efficient dissolution of fibrin clots, it is sterically pro-
tected when bound to fibrin from inhibition by A2AP (24). Inhi-
bition by A2AP requires the presence of a free active site and
free lysine-binding sites in plg/plm; these are inaccessible when
plg/plm is bound to substrates such as fibrin (21–23). We tested
whether or not plm was also protected from A2AP inhibition
when bound to amorphous protein aggregates. We first sepa-
rated end point aggregation mixtures of SOD and OVO by cen-
trifugation (15,000  g for 30 min) into fractions designated as
soluble and insoluble before separately testing them in the col-
orimetric plg activation assay with and without A2AP. The sol-
uble fraction would be expected to contain a mixture of small
aggregates and monomeric protein molecules, whereas the
insoluble fraction would contain large protein aggregates. For
SOD and OVO, both the soluble and insoluble fractions elicited
significant plg activation (supplemental Fig. 1). Although A2AP
inhibited 70 –75% of the plm activity generated by soluble
protein fractions, it was only able to inhibit 27– 42% of the
corresponding activity elicited by insoluble protein fractions
(Fig. 2, E and F). Thus, when associated with large, insoluble
amorphous protein aggregates, plm is relatively resistant to
inhibition by A2AP.
Plasmin digests amorphous protein aggregates to generate
heterogeneously sized and hydrophobic protein fragments
Amorphous protein aggregates prepared as described above
were digested with plm to generate soluble fragments (amor-
phous aggregate-derived plasmin-generated protein fragments
(amorphPGPFs)), which were then analyzed together with whole
(undigested) protein aggregates by reducing SDS-PAGE.
Native proteins were also digested with plm under the same
conditions to generate experimental controls (nativePGPFs).
Most of the SOD and OVO aggregates were too large to enter
the SDS-polyacrylamide gel and accumulated at the top of the
resolving gel (Fig. 3A). Other minor species that entered the gel
are likely to represent smaller aggregates. The digestion of
aggregated SOD yielded amorphPGPFs ranging in size from 15 to
200 kDa that appeared as a smear with no visually distinct
bands. Digestion of aggregated OVO yielded amorphPGPFs
ranging in size from 88 to 164 kDa and a smear of other visually
indistinct bands less than 75 kDa in size. Autolysis of plm
resulting from prolonged incubation (	2 h at neutral pH) in
aqueous solution was evident based on the fact that bands cor-
responding to plm heavy chain (63 kDa) and light chain
(26.5 kDa) (25) are not easily visually resolved from those
detected in PGPF preparations. PGPFs, together with their par-
ent proteins/aggregates and other controls, were also analyzed
for exposed hydrophobicity in a bisANS fluorescence assay
(Fig. 3B). In all cases, aggregates and their corresponding
amorphPGPFs, but not native proteins or the corresponding
nativePGPFs, had significantly higher bisANS fluorescence than
wells containing only bisANS (Fig. 3B). Additionally, amor-
phous protein aggregates had 30% greater bisANS fluores-
cence than the corresponding amorphPGPFs (a significant dif-
ference). Relative to bisANS alone, SOD aggregates and
Figure 1. Heat or chemical stress induces increased exposed hydrophobicity and aggregation of SOD and OVO into -sheet-poor, non-fibrillar
amorphous aggregates. SOD (A) and OVO (B) were induced to aggregate as described under “Experimental procedures.” Exposed hydrophobicity and
aggregation were measured as changes in relative bisANS-associated fluorescence (AFU) and turbidity (A360) over time, respectively. C, Thio-T was incubated
in the absence or presence of samples (5 M) of either SOD or OVO aggregates taken postaggregation (300 and 	34 min, respectively) or control proteins,
and the level of -sheet content was measured as the relative Thio-T fluorescence intensity. Fibrillar aggregates of SH3 and native BSA were used as positive
and negative control proteins, respectively. Data points in A–C represent the mean of three separate experiments, each performed in triplicate (n  9; error bars
represent S.E.). D, representative scanning electron micrographs of SOD and OVO aggregates taken postaggregation (300 and 34 min, respectively). Amor-
phous aggregates are present. White scale bars represent 1 m.
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amorphPGPFs had, respectively, 2.7- and 2.1-fold greater
bisANS fluorescence. The corresponding values for OVO
aggregates and amorphPGPFs were 3.5- and 2.8-fold, respec-
tively. The fluorescence of wells containing native SOD or OVO
or the corresponding nativePGPFs was not significantly greater
than that of bisANS alone (Fig. 3B).
amorphPGPFs bind to multiple cell surface receptors and are
trafficked to lysosomes
amorphPGPFs were labeled with CF-488 (Biotium;
amorphPGPFs488), purified by size exclusion chromatography,
and then incubated with EOC 13.31 or SVEC4-10 cells. When
incubated with cells on ice (to inhibit endocytosis), there was
measurable binding of amorphPGPFs488 to the surface of both
cell types, and this binding could be partially inhibited by a
range of inhibitors of cell surface receptors in a cell- and pro-
tein-specific manner (Table 1). Lipopolysaccharide (LPS) and
methyl--cyclodextrin (M--CD) significantly inhibited the
binding of SOD amorphPGPFs488 to EOC 13.31 cells by 58 and
37%, respectively, suggesting that toll-like receptors and lipid
rafts may be facilitating cell surface binding. M--CD also sig-
nificantly inhibited the binding of SOD amorphPGPFs488 to
SVEC4-10 cells by  23%, again suggesting an involvement of
lipid rafts. The binding of OVO amorphPGPFs488 to EOC 13.31
cells was significantly inhibited by receptor-associated protein
(RAP), M--CD, LPS, and mannan (by 47, 26, 22, and 19%,
respectively), suggesting the involvement of LDL family recep-
tors, lipid rafts, toll-like receptors, and the mannose receptor in
the binding. None of the inhibitors tested affected the binding
of OVO amorphPGPFs488 to SVEC4-10 cells, indicating that dif-
ferent processes may be involved in this case. In the case of
OVO amorphPGPFs488 (but not SOD amorphPGPFs488), both
CLU and A2M partially inhibited binding to both cell types (Fig.
4). CLU inhibited the binding of OVO amorphPGPFs488 to EOC
Figure 2. Plg activation assays. A and B, aggregated or native non-aggregated protein sample or fibrin as a positive control (all at 75 g/m) were preincubated
in the presence of 250 nM plg and 500 nM SPEC-PL. The reaction was initiated by the addition of 5 nM tPA, and the change in A405 was recorded. tPA/plg alone
and fibrin served as controls for plg activation in the absence or presence of cofactor, respectively. Data points represent the mean of three separate
experiments, each performed in triplicate (n  9; error bars represent S.E.). C–F, bar graphs showing results from other assays in which protein aggregates (C and
D) or soluble and insoluble fractions prepared from aggregation mixtures (E and F) (all at 75 g/ml) were incubated first for 30 min with 5 nM tPA and 250 nM
plg and then for 15 min with or without specific inhibitors (C and D, 10 mM TXA; E and F, 400 nM A2AP) before adding the plm substrate and measuring changes
in A405 as described previously. Data shown are means of three replicates (error bars represent S.D.) and correspond to 120-min time points, which in these
assays were when the A405 had reached a maximum. Significant differences are indicated. The results shown are representative of two independent experi-
ments. Agg., aggregates.
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13.31 and SVEC4-10 cells by 30 and 34%, respectively, and
to SVEC4-10 cells by 24 and 35%, respectively. Thus, the
results indicate considerable heterogeneity in the mecha-
nism(s) by which PGPFs interact with the cell surface and that,
in at least some cases, ECs can partially inhibit the cell surface
binding of PGPFs.
When incubated with EOC 13.31 or SVEC4-10 cells at 37 °C
for periods of 1– 4 h, confocal microscopy analyses showed that
both OVO and SOD amorphPGPFs488 were internalized and that
the intracellular fluorescence was punctate, consistent with an
intravesicular location, and in time overlapped with that of
LysoTracker staining (Fig. 4C; SVEC4-10 cells shown). A simi-
lar pattern of fluorescence was observed for both types of cells
stained with LysoTracker following 1– 4-h incubation under
the same conditions with either fluor-labeled OVO or BSA (not
shown). These results are consistent with internalized PGPFs
following the classic endocytosis route and being trafficked to
lysosomes for degradation.
amorphPGPFs are cytotoxic and are specifically bound by ECs
Colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-
thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assays
were used to test whether or not amorphPGPFs and nativePGPFs
derived from SOD and OVO and the native parent proteins
were cytotoxic to EOC 13.31 and SVEC4-10 cells. For both cell
types, amorphPGPFs derived from SOD and OVO aggregates
were toxic. Relative to the PBS only-added control, under the
conditions tested, SOD amorphPGPFs reduced the viability of
EOC 13.31 and SVEC4-10 cells by 72 and 45%, respectively;
the corresponding reductions in viability for OVO amorphPGPFs
were 44 and 55%, respectively (Fig. 5). In contrast, in all
cases, the viability of cells incubated with nativePGPFs was not
significantly different from the control (Fig. 5); the native par-
ent proteins were also not significantly toxic (supplemental Fig.
3). CLU, A2M, and BSA also had no significant effect on
cell viability (supplemental Fig. 3). However, the toxicity of
amorphPGPFs was significantly reduced by preincubating them
with CLU or A2M and in the case of SOD amorphPGPFs main-
tained viable cell numbers at or above that of the control. Pre-
incubation of SOD amorphPGPFs with CLU actually resulted in a
significant increase in viable SVEC4-10 cell numbers above that
of the control (Fig. 5B). The toxicity of amorphPGPFs was also
confirmed in separate experiments in which dead cells were
stained with the membrane-impermeant nucleic acid stain
SYTOX Green (supplemental Fig. 4). PGPF preparations had
negligible residual plm activity (data not shown), and thus
Figure 3. Plm digests amorphous protein aggregates to generate soluble PGPFs that have increased hydrophobicity relative to native proteins. A,
samples of amorphously aggregated SOD and OVO taken from in vitro aggregation assays were diluted in PBS and incubated with or without 100 milliunits of
plm overnight at 37 °C to yield PGPFs and undigested aggregates (Agg.) respectively, as indicated. Samples were then analyzed under reducing conditions on
12% Tris-Tricine gels and stained with Coomassie Blue. Molecular masses of protein standards are indicated in kDa (M). B, bisANS-associated fluorescence (AFU)
was used to measure exposed hydrophobicity for samples of aggregated protein (Agg.), amorphPGPFs, and native protein diluted to 200 g/ml in PBS. This was
compared with nativePGPFs and bisANS alone. Bars represent the mean of three independent experiments performed in triplicate (n  9; error bars represent
S.D.). Significant differences are indicated.
Table 1
Effects of various inhibitors on the binding of amorphPGPF488 to cells at 4 °C
Cells were incubated in ice-cold BSA/PBS/Az for 30 min in the presence or absence of inhibitor and then incubated for a further 30 min in the same buffer containing 20
g/ml amorphPGPFs488. Cells were then washed and analyzed by flow cytometry. Mean fluorescence intensity S.D. (n  9) of three independent experiments performed
in triplicate for each inhibitor is shown. Dashes (—) denote that no significant inhibition was measured. RAP, receptor-associated protein; TLR, toll-like receptor; LDLRs,
LDL receptors.
Cell line amorphPGPF488










EOC 13.31 SOD 57.5  7.8 — 37.3  5.8 —
EOC 13.31 OVO 21.5  7.4 19.2  5.2 25.7  0.1 46.9  7.9
SVEC4-10 SOD — — 23.3  7.2 —
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any cytotoxicity measured was attributable to the PGPFs
themselves.
Given the demonstrated protective effects of CLU and A2M
against the toxicity of amorphPGPFs, we used a capture ELISA
approach to test whether or not ECs bind specifically to
amorphPGPFs. In these assays, specific anti-EC (or control) anti-
bodies were coated onto the microplate wells and subsequently
incubated with biotinylated amorphPGPFs or nativePGPFs that
had been preincubated with (or without) ECs. In other controls,
antibody-coated ELISA wells were incubated with biotinylated
amorphPGPFs alone or a mixture of these together with BSA as a
non-chaperone control protein. If biotinylated species formed
complexes with ECs in solution, then the respective anti-EC
antibody was expected to specifically capture these complexes
from solution. These assays detected significant binding of CLU
and A2M to amorphPGPFs generated from both SOD and OVO
but not to the corresponding nativePGPFs. There was also neg-
ligible binding detected when wells were incubated with bioti-
nylated amorphPGPFs alone or a mixture of these with BSA (Fig.
6). Thus, the results indicate that CLU and A2M both specifi-
cally bind to amorphPGPFs to form soluble complexes, and it is
likely that this interaction underpins the ability of ECs to pro-
tect cells against the toxicity of amorphPGPFs.
ECs do not interact with PGPFs generated from fibrin
Fibrin clots are not amorphous in structure. On the contrary,
thrombin-mediated proteolysis of fibrinogen leads to the
assembly of fibrin into a polymer with a very defined and repet-
itive structure rich in cross--sheets (26). The classic fibrino-
lytic activity of the PAS is known to digest fibrin to yield a
number of specific protein fragments of which one, fibrin frag-
ment E, induces apoptosis in various cell types (9). Given our
demonstration that ECs specifically bind to and inhibit the tox-
icity of PGPFs generated from amorphous protein aggregates,
we examined whether ECs might also interact with PGPFs
generated by the plasmin-mediated digestion of fibrin (i.e.
fibrinPGPFs). SDS-PAGE (Fig. 7A) analyses of fibrinPGPF prepa-
rations were consistent with previously published studies (13)
and the presence of the expected D and E fragments (95 and
41–50 kDa, respectively; Fig. 7A). Two different ELISA pro-
tocols were performed to detect whether or not fibrinPGPFs
Figure 4. Cell binding and internalization of amorphPGPFs. EOC 13.31 (A) or
SVEC4-10 (B) cells were incubated for 30 min in the presence or absence of 20
g/ml SOD or OVO amorphPGPFs488 in ice-cold BSA/PBS/Az following preincu-
bation with or without 100 g/ml CLU or A2M. Cells were then washed and
analyzed by flow cytometry. Results are displayed as the mean fluorescence
intensity (MFI) of three independent experiments performed in triplicate
(n  9; error bars represent S.E.). C, representative confocal microscope
image showing overlay of transmission image, green fluorescence (OVO
amorphPGPFs488), and red fluorescence (LysoTracker Red DND-99) for
SCEV4-10 cells following a 2-h incubation with 50 g/ml OVO amorphPGPFs488.
Areas appearing in yellow (white arrows) indicate co-localization of internal-
ized amorphPGPFs488 and lysosomes. The scale bar indicates 25 m.
Figure 5. amorphPGPFs are cytotoxic. Sterile samples of amorphPGPF or
nativePGPF derived from SOD or OVO were preincubated for 1 h at 37 °C in the
presence or absence of CLU or A2M or with BSA (non-chaperone control
protein) (all proteins at 400 g/ml) before incubating the PGPFs at a final
concentration of 200 g/ml with EOC 13.31 (A) and SVEC4-10 (B) cells at 37 °C
for 24 h (see key). The MTS assay was then performed, and results are plotted
as a percentage of the A490 for PBS only-added control wells (dashed line; see
also supplemental Fig. 2). The results are pooled from three independent
experiments done in triplicate and are plotted as means (n  9; error bars
represent S.D.). Significant differences between groups are indicated, and
asterisks above individual bars indicate that the sample is significantly differ-
ent from the PBS only-added control (*, p 
 0.001).
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bound to ECs (Fig. 7, B and C). In the first protocol, purified ECs
were immobilized on the plate, and any subsequent binding of
biotinylated fibrinPGPFs was measured (Fig. 7B). The second
protocol was essentially the same capture assay used previously
to demonstrate the formation of EC–amorphPGPFs complexes.
Purified anti-EC antibodies were immobilized on the plate and
used to capture from solution ECs or any complexes formed
between these and biotinylated fibrinPGPFs during a preincuba-
tion step (Fig. 7C). No specific binding between ECs and
PGPFs was detected using either of the two ELISA protocols.
Furthermore, size exclusion chromatographic analysis of ECs,
fibrinPGPFs, and mixtures of ECs and fibrinPGPFs failed to detect
any evidence of the formation of EC–fibrinPGPF complexes
(supplemental Fig. 5). Collectively, the results strongly indicate
that ECs do not interact with fibrinPGPFs.
Discussion
Using heat and chemical reduction, we generated aggregates
from two model proteins, SOD and OVO, respectively. These
aggregates were characterized by thioflavin T assay and elec-
tron microscopy as being non-amyloid and physically amor-
phous in structure. BisANS assays demonstrated that during
aggregation the aggregating species showed a time-dependent
increase in exposed hydrophobicity. These protein aggregates
were shown to act as efficient cofactors for the tPA-mediated
activation of plg to plm, producing similar levels of plm activity
under the conditions tested as fibrin. Earlier reports had
described physically or chemically denatured proteins as stim-
ulating the PAS (15, 17) and established that chemical treat-
ment of these denatured proteins to modify lysine (but not
other amino acid) side chains abolished this activity (16). In
contrast, lysine residues do not appear to be required for the
corresponding activity of amyloid, which instead appears de-
pendent on cross- structure (27). The current study confirms
that cross- structure is not essential for stimulation of the PAS
and that protein aggregates of an apparently entirely amor-
phous structure are sufficient to stimulate tPA-dependent acti-
vation of plm. Furthermore, the demonstration that TXA (a
lysine analogue) significantly inhibits the ability of amorphous
protein aggregates to elicit plg activation implies that lysine
Figure 6. amorphPGPFs are specifically bound by ECs. Shown are results of capture ELISA in which wells were coated with anti-chaperone or control antibodies and
incubated with mixtures of CLU or A2M and biotinylated amorphPGPFs or nativePGPFs derived from SOD (A) or OVO (B). Biotinylated proteins subsequently bound to the
wells were detected with a complex formed with streptavidin and biotinylated horseradish peroxidase (see “Experimental procedures”). In other controls, antibody-
coated ELISA wells were incubated with only biotinylated amorphPGPFs (PGPF alone) or a mixture of this together with BSA as a non-chaperone control protein
(PGPF/BSA). Bars represent the mean of three independent experiments performed in triplicate (n  9; error bars represent S.D.; *, p 
 0.001).
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residues are necessary for the interactions between amorphous
protein aggregates and tPA/plg that underpin plg activation
(Fig. 2). When end point samples from the amorphous protein
aggregation mixtures were separated by centrifugation into
fractions designated as soluble and insoluble, both fractions
were able to stimulate activation of plg to plm, but these frac-
tions showed a different sensitivity to inhibition by A2AP. The
soluble fraction, which would contain smaller protein aggre-
gates that do not pellet during the low-speed centrifugation
conditions used, were more sensitive to A2AP inhibition,
whereas the larger aggregates present in the centrifugal pellet
were significantly more resistant to inhibition by A2AP (Fig. 2).
In this respect, the larger, insoluble amorphous aggregates
showed a similar resistance to inhibition by A2AP as fibrin, the
classic cofactor for the PAS (18).
Digestion of amorphous aggregates of SOD and OVO by plm
was efficient and generated smaller, soluble fragments distrib-
uted over a broad range of sizes (Fig. 3). During an 8-h incuba-
Figure 7. fibrinPGPFs do not interact with ECs. A, image of a Coomassie Blue-stained non-reducing 10% SDS-polyacrylamide gel loaded with 10 g of
fibrinPGPFs. Expected positions of fragments containing single D domains (95 kDa) and E domains (41–50 kDa) are indicated to the right, and positions of
molecular mass markers are given on the left (mass in kDa). B and C, histograms showing the results of two ELISA protocols used to detect binding of ECs to
fibrinPGPFs. B, binding of biotinylated fibrinPGFPs (20 g/ml) to immobilized CLU and A2M. Wells coated with biotinylated PGPFs acted as positive controls, and
wells coated with ECs and incubated only with blocking buffer acted as negative controls. C, immobilized anti-EC antibodies were used to capture any
complexes formed in solution between biotinylated fibrinPGFPs and CLU or A2M in solution. Wells coated with biotinylated fibrinPGPFs were used as positive
controls, and wells coated with anti-EC antibodies and incubated only with ECs were used as negative controls. Values shown represent the mean (n  3; error
bars represent S.E.). All absorbance values were corrected for the background control consisting of wells coated only with blocking buffer (HDC/PBS) and then
treated as for other corresponding wells.
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tion at 37 °C, 100 milliunits of plm generated 3.13 mg of soluble
amorphPGPFs from 4 mg of SOD aggregate in 120 l (deter-
mined using bicinchoninic acid (BCA) assay; not shown). This
activity is similar to that reported for the in vitro degradation of
aggregated A by plm (28). Concentrations of plm used to gen-
erate PGPFs from amorphous aggregates (1.8 M) were sim-
ilar to that reported for plg in plasma (1.6 –2 M) (29, 30). Free
active plasmin concentrations in human plasma are usually low
(0.02 IU/ml) except in cases of antiplasmin deficiency (31) or
thrombolytic therapy (32). The resting cerebrospinal fluid con-
centrations for plg are reported to be much lower than plasma
concentrations (3–15 nM) (33); however, this appears sufficient
to allow the degradation of A peptide in mice (34). Addition-
ally, the concentration of plg in cerebrospinal fluid is further
increased during breakdown of the blood– brain barrier (33)
that occurs, for example, in Alzheimer’s disease (35, 36).
Like the parent protein aggregates, relative to the corre-
sponding native proteins, the amorphPGPFs have relatively high
levels of surface-exposed hydrophobicity, which is a character-
istic feature of protein species that interact with ECs (37). The
levels of bisANS fluorescence measured for amorphPGPFs
approached those of the corresponding undigested aggregates,
which are typical of those measured for other unfolded protein
samples (38). The binding of CLU and A2M (both ECs) to the
amorphPGPFs was clearly demonstrated by the specific immu-
nocapture of EC–PGPF complexes by immobilized anti-EC
antibodies (Fig. 6). When incubated alone with EOC 13.31 or
SVEC4-10 cells, the amorphPGPFs bound by a variety of cell- and
protein-specific mechanisms to the cell surface (Table 1).
The level of fluorescence measured for cell-associated
amorphPGPF488 was of the same order as that previously
reported for the binding of fluor-labeled EC– client protein
complexes to human peripheral blood cells (39) and in both
cases resulted in their progressive internalization into vesicular
structures and trafficking to lysosomes, easily detected by con-
focal microscopy (Fig. 4). Thus, PGPF uptake appears to follow
a classic endocytic route.
Notably, when amorphPGPFs were presented to cells alone,
they were significantly cytotoxic. Historically, amorphous pro-
tein aggregates have been regarded as generally non-toxic to
cells despite their occurrence in many protein deposition
diseases. Results presented here, however, show that for both
SOD and OVO amorphous aggregates and amorphPGPFs are
cytotoxic, whereas the corresponding native proteins and
nativePGPFs are not. This suggests that, as is the case for the
toxicity of prefibrillar amyloid-forming oligomers (40 – 42), the
cytotoxicity of amorphous aggregates and the PGPFs derived
from them is independent of amino acid sequence and arises
instead from a structural or conformational feature. The pre-
cise nature of this feature remains to be characterized but is
likely to involve regions of exposed hydrophobicity (43). The
binding of SOD-derived amorphPGPFs to cells was less than that
of OVO-derived amorphPGPFs (Fig. 4), but, nevertheless, overall
the former appeared to be more cytotoxic (Fig. 5). This is
entirely consistent with the observation that amyloid aggre-
gates generated from different proteins have varied levels of
cytotoxicity (42, 44), suggesting that the same is true of PGPFs
generated from different amorphous protein aggregates.
Under the conditions tested, all (or almost all) of the cytotox-
icity was inhibited by preincubation of CLU or A2M with the
amorphPGPFs, whereas the addition of the chaperones to cells in
the absence of PGPFs had no significant effect on the numbers
of viable cells (Fig. 5 and supplemental Fig. 3). This indicates
that, similar to their effects on toxic protein oligomers (45, 46),
the formation of soluble complexes between ECs and hydro-
phobic amorphPGPFs neutralizes the cytotoxicity of the latter.
The reason(s) for the significant increase in viable SVEC4-10
cell numbers, relative to the PBS control, in cultures treated
with a preincubated mixture of SOD amorphPGPFs and CLU
(but not CLU alone; Fig. 5B and supplemental Fig. 3) is unclear
but could result from a cell type-specific proliferative signaling
effect of the CLU–amorphPGPFs complexes.
As previously mentioned, the action of plm on fibrin clots
also releases PGPFs, which are known to be cytotoxic. However,
unlike amorphous protein aggregates, the structure of fibrin is
highly ordered, and its digestion by plm releases a relatively
small number of fragments corresponding to defined structural
elements of the fibrin lattice (Fig. 7A). The cytotoxicity of
fibrinPGPF has been identified as arising from a sequence-de-
fined rather than a conformational epitope in fibrin fragment E
contained within amino acids 17–104 of the A-chain (9). This
fundamental difference between amorphPGPFs and fibrinPGPFs
probably explains why CLU and A2M did not interact with
fibrinPGPFs (Fig. 7B and supplemental Fig. 5). ECs and chaper-
ones in general do not bind to specific amino acid sequences but
rather bind promiscuously to exposed regions of hydrophobic-
ity on misfolded proteins (47).
Collectively, results presented here and elsewhere show that
the PAS satisfies the criteria to play an important role in extra-
cellular proteostasis. Insoluble protein aggregates, whether
they are amorphous or amyloid in structure, specifically trigger
the PAS to generate active plm, which is able to efficiently
degrade the aggregates. Like soluble amyloid oligomers,
amorphPGPFs are cytotoxic, and both types of species have
increased hydrophobicity relative to the parent native proteins
(48). In both cases, it is likely that ECs bind to these species via
regions of exposed hydrophobicity and thereby act to neutralize
their toxicity to cells. The toxicity of PGPFs generated by plm-
mediated digestion of amyloid fibrils or their interactions with
ECs has yet to be tested. ECs have previously been strongly
implicated in clearing misfolded proteins from body fluids (1,
39). The current data are consistent with a hypothetical model
in which the PAS functionally synergizes with ECs in vivo, the
PAS first acting to degrade insoluble extracellular protein
deposits to release smaller, soluble PGPFs, which are then
incorporated into complexes with ECs to neutralize any toxicity
and safely transport them in body fluids for subsequent uptake
and disposal. This process could be important in clearing and
disposing of both proteinaceous debris released during tissue
injury (12, 49) and large extracellular protein deposits formed
as part of disease pathologies.
It is interesting to note that in the brains of transgenic mice
overexpressing human amyloid precursor protein larger and
more numerous A plaques were present in heterozygous tPA
knock-out mice (homozygous knock-out is fatal) than in con-
trol mice (50). Furthermore, relative to controls, plg/ mice
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had elevated levels and delayed clearance of extracellular mis-
folded tubulin aggregates following neurotrauma (49). Consist-
ent with our hypothetical model, these results suggest that the
PAS may have been required for the efficient in vivo removal of
extracellular protein aggregates in these systems. Future work
is required to clarify the potential roles of ECs in these types of
important in vivo clearance mechanisms and their function in
maintaining organismal viability and disease control.
Experimental procedures
Materials
CLU and A2M were purified from human plasma as
described previously (51, 52). OVO and all chemicals were
obtained from Sigma-Aldrich unless otherwise specified. The
G93A mutant of SOD was expressed as a recombinant product
in Escherichia coli and purified by ammonium sulfate fraction-
ation and size exclusion chromatography as described previ-
ously (53).
Protein aggregation assays
Amorphous aggregation of proteins in 96-well microplates
(100 l/well) was monitored by measuring turbidity (changes in
absorbance at 360 nm) using a FLUOstar or POLARstar spec-
trophotometer (BMG Labtech). Proteins were induced to
aggregate in PBS (135 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl,
1.75 mM KH2PO4, pH 7.4) as follows. OVO (1.5 mg/ml) was
heated at 60 °C for 120 min, and SOD (1.4 mg/ml) was incu-
bated with 50 mM DTT and 5 mM EDTA at 37 °C for 24 h.
Aggregation mixtures were snap frozen in liquid nitrogen at
different time points for use in later experiments.
BisANS and thioflavin T assays
Samples of amorphously aggregated proteins, native pro-
teins, amorphPGPFs, or nativePGPFs derived at 200 g/ml; BSA
at 300 g/ml (as a positive control); or no addition (as a negative
control) in PBS were supplemented with 100 M bisANS, and
the relative bisANS-associated fluorescence was recorded
using a POLARstar spectrophotometer and excitation and
emission band pass filters of 355  5 and 490  5 nm, respec-
tively. BSA (300 g/ml) in PBS was used as a positive control for
exposed hydrophobicity. Thioflavin T (Thio-T) assays were
performed to measure -sheet structure generated during amy-
loid aggregation. Samples taken at different time points during
protein aggregation assays at a final concentration of 0.75
mg/ml were supplemented with 25 M Thio-T, and the relative
fluorescence was recorded using a POLARstar spectrophotom-
eter and excitation and emission band pass filters of 440  5 and
490  5 nm, respectively. BSA (0.75 mg/ml) was used as a neg-
ative control. Fibrillar aggregate formed from the SH3 domain
of the p85 subunit of bovine phosphatidylinositol 3-kinase
was kindly donated by Dr. Justin Yerbury (54) and used as a
positive control (also at 0.75 mg/ml).
Scanning electron microscopy
Samples taken from the end points of protein aggregation
assays were resuspended at a total protein concentration of 0.1
mg/ml in PBS, and 2 l of each sample was blotted onto Form-
var resin (with carbon coating) nickel mesh grids (Proscitech),
incubated for 5 min at room temperature, washed three times
with filtered distilled H2O, and negatively stained with 1% (w/v)
uranyl acetate in Milli-Q H2O for a further 5 min at room tem-
perature. Specimens were examined using a JSM7500FA cold
field emission gun scanning electron microscope (JEOL) with
an acceleration voltage of 20.0 kV and a working distance of 8
mm (spot size setting of 8).
SDS-PAGE and BCA assays
Protein aggregates and soluble PGPFs were analyzed by 12%
resolving Tris-Tricine SDS-PAGE under reducing conditions
and stained with Coomassie Blue stain. The molecular weight
standards used were from Fermentas. The BCA microplate
assay was performed using 384-well plates following the man-
ufacturer’s instructions (Sigma); BSA was used as a standard.
The concentrations of aggregated protein samples were treated
as equivalent to the starting concentration of native protein at
the beginning of the corresponding aggregation time course.
Plasminogen activation assays
Samples from protein aggregation assays were dialyzed into
HBST (10 mM HEPES, 150 mM NaCl, 0.01% (v/v) Tween 20, pH
7.4). In some experiments, aggregate mixtures were first centri-
fuged at 15,000  g for 30 min at 4 °C to separate the mixtures
into soluble and insoluble fractions prior to dialysis. The con-
centration of soluble fractions was determined by BCA assay;
the mass concentration of insoluble fractions was estimated by
calculating the difference between the protein concentration at
the start of the aggregation time course and that of the soluble
fraction prepared from the end point of the aggregation mix-
ture. The ability of samples to induce tPA-mediated plg activa-
tion to plm was measured as a change in absorbance resulting
from the conversion of the plm-specific chromogenic substrate
H-D-norleucyl-hexahydrotyrosol-lysine-para-nitroanilide
diacetate (SPEC-PL; American Diagnostica Inc.) to para-nitro-
aniline. In a 96-well polystyrene microplate (Greiner Bio-one),
native or amorphously aggregated protein sample or fibrin
(positive control) at an initial concentration of 75 g/ml in ice-
cold HBST (60 l/well) was incubated with 250 nM plg and 500
nM SPEC-PL in a 96-well polystyrene microplate. Solubilized
fibrin stock (25 mg/ml) was prepared according to the manufa-
cturer’s instructions (Sigma-Aldrich) and stored aliquoted at
20 °C. The reaction was initiated by adding 10 l of recombi-
nant human tPA (Actilyse, Roche Applied Science) to a final
concentration of 5 nM/well. Absorbance at 405 nm (A405) was
measured on a Spectramax Plus 382 plate reader (Molecular
Devices) for 120 min at 37 °C with measurements taken at 30-s
cycles with 3 s of shaking between cycles. For quantitative anal-
yses, the initial rate of change of plm activity (initial rate of
reaction) was calculated from the gradient of the change in A405
versus t2 (t2 was used to linearize the curves and simplify calcu-
lation). Data transformation and linear regressions were per-
formed using GraphPad Prism v5.0 (GraphPad Software). In
other experiments, the same concentrations as above of tPA,
plg, and the protein aggregate sample were first incubated
together in HBST for 30 min at 37 °C and then incubated (or
not) with 10 mM TXA or 400 nM A2AP for a further 15 min
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prior to measuring plm activity. Various background controls
were included in all assays including tPA/SPEC-PL, plg/SPEC-
PL, SPEC-PL alone, OVO/SPEC-PL, OVO/plg/SPEC-PL,
OVO/tPA/SPEC-PL, etc.). The A405 associated with these was
always small or negligible but was subtracted where appropri-
ate from the raw data.
Plasmin digestion of amorphous protein aggregates
Native proteins were sterilized by filtration through a 0.2-
m-pore-size membrane and induced to aggregate under con-
ditions described above. Samples taken from protein aggrega-
tion assays were centrifuged at 15,000  g for 15 min at 4 °C,
and the pellet was resuspended in PBS to 1 mg/ml. Plm (100
milliunits; Hematologic Technologies, Inc.) was added to 100
l of the suspended aggregates to give a final total volume of 120
l and incubated overnight with shaking at 37 °C. Native pro-
tein samples were also plm-digested under the same conditions.
Insoluble, undigested material was removed by centrifugation
at 15,000  g for 15 min at 4 °C. The concentration of soluble
PGPFs in the supernatant was determined by BCA assay. Neg-
ligible plasmin activity was measured in PGPF preparations
(data not shown).
Conjugation of PGPFs
Biotinylation of PGPFs was performed using biotin-LC-NHS
according to the manufacturer’s instructions (Thermo Fisher).
Unreacted biotin-LC-NHS was removed by dialysis against
three changes of PBS, 0.1% azide at 4 °C. PGPFs at 1 mg/ml in
PBS (adjusted to pH 8.3 with 1 M Na2HCO3) were incubated
with CF-488 SE with gentle shaking for 1 h at room temperature
while protected from light. Unreacted CF-488 was subse-
quently removed by size exclusion chromatography, and the
concentrations of CF-488-conjugated PGPFs (PGPFs488) were
subsequently determined using a BCA assay.
ELISA
For direct binding ELISA, plates (384-well) were coated with
10 g/ml purified human clusterin or A2M. Unless otherwise
indicated, all additions to wells were of 30-l volumes, incuba-
tions were for 1 h at 37 °C, and wash steps were performed with
shaking; plates were washed six times with PBS containing 0.1%
(v/v) Tx-100 (Tx-100/PBS) followed by six washes with PBS.
Wells were then blocked with 50 l/well 1% (w/v) heat-dena-
tured casein in PBS (HDC/PBS) before incubating with 20
g/ml biotinylated PGPFs in HDC/PBS. Following washing,
bound biotinylated proteins were detected using a mixture of
2.5 g/ml each of streptavidin and biotinylated HRP in HDC/
PBS. Finally, color was developed with the addition of 30
l/well 2.5 mg/ml o-phenylenediamine dihydrochloride in 50
mM dibasic sodium phosphate, 25 mM citric acid, pH 5.0, sup-
plemented with 0.03% (w/v) H2O2 and incubation for 5 min at
room temperature, and the reaction was stopped with the addi-
tion of 30 l/well 1 M HCl. For capture ELISA, wells were first
coated with 10 g/ml G7 anti-CLU monoclonal antibody,
mouse anti-human A2M monoclonal antibody (Abcam,
ab58703), or isotype control antibody (mouse IgG1 antibody;
Millipore) in PBS and then blocked as above. Before incubating
on the blocked plate, biotinylated PGPFs at 50 g/ml in 1%
(w/v) BSA in Tx-100/PBS were preincubated for 1 h at 37 °C
with or without 20 g/ml CLU or A2M or with BSA (as a non-
chaperone control protein). Bound biotinylated proteins were
detected as above. For all ELISAs, the A490 was measured using
a Spectramax Plus 382 plate reader. Absorbances from wells
coated with isotype control antibody were subtracted from cor-
responding wells coated with G7 anti-CLU and anti-A2M
antibodies.
Cell culture
EOC 13.31 (microglial-like), SVEC4-10 (endothelial-like),
and LADMAC (monocyte-like) murine cell lines were obtained
from the American Type Culture Collection. Cell lines were
grown in DMEM/F-12 (Life Technologies) containing 10%
(v/v) fetal calf serum (FCS) at 37 °C and 5% CO2 and subcul-
tured when they reached 80% confluence. EOC 13.31 cells were
additionally supplemented with 20% (v/v) LADMAC-condi-
tioned medium (which contains secreted colony-stimulating
factor-1). For experiments involving the addition of chaper-
ones, in an effort to limit the effects of bovine chaperones that
may be present in the FCS, cells were incubated with treatments
in DMEM/F-12 containing only 1% (v/v) FCS.
Binding of PGPFs to cells
EOC 13.31 and SVEC4-10 cells were harvested using Stem-
Pro Accutase (Life Technologies) (which does not cleave cell
surface proteins) and resuspended in ice-cold 1% (w/v) BSA,
PBS, 0.1% (w/v) NaN3 (BSA/PBS/Az). PGPFs488 were preincu-
bated with or without CLU or A2M in PBS for 1 h at 37 °C (all
proteins at 400 g/ml) before diluting to a final concentration
of 20 g/ml in BSA/PBS/Az and incubating with cells for 30
min on ice. In other experiments, cells were preincubated for 30
min in ice-cold BSA/PBS/Az, with or without each of the
specific inhibitors shown in Table 1, before incubating with
PGPFs488 as before. Following incubations, cells were washed
and resuspended in BSA/PBS/Az before flow cytometric anal-
ysis; cells incubated only in BSA/PBS/Az were used as the neg-
ative control in these assays. Non-viable cells were stained with
1 M propidium iodide and excluded from analyses by elec-
tronic gating. Flow cytometry was performed using a Fortessa
X-20 instrument and FACSDiva v8.0 acquisition software (BD
Biosciences). Fluorescence was collected using excitation at 488
nm and emissions at 525  25 nm (CF-488) and 695  20 nm
(propidium iodide). Data analysis was performed using FlowJo
software (v10.2 for Macintosh; FlowJo, LLC).
Confocal microscopy
Cells were grown in 8-chamber -slides (Ibidi). LysoTracker
Red DND-99 (50 nM; Invitrogen) and PGPFs488 (20 –100
g/ml) were added to the slide chambers and incubated for 1– 4
h before washing with phenol red-free DMEM/F-12. Images for
PGPF488 and LysoTracker Red DND-99 fluorescence were then
collected sequentially using an inverted Leica SP5 confocal
microscope (Leica Microsystems, Sydney, Australia). Excita-
tion lasers and emission collection windows used were, respec-
tively, 488 and 510 –580 nm for PGPFs488 and 561 and 600 –700
nm for LysoTracker Red DND-99. A transmission image was
also collected using the 488 nm laser as the light source.
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PGPFs were preincubated with or without CLU or A2M or
with BSA as a non-chaperone control protein in PBS for 1 h at
37 °C (all proteins present at 1 mg/ml). They were then added to
cultures of EOC 13.31 or SVEC4-10 cells such that each protein
added had a final concentration of 200 g/ml and incubated for
24 –90 h at 37 °C and 5% (v/v) CO2. The MTS assay was per-
formed using a CellTiter 96 AQueous One Solution Cell Prolif-
eration Assay kit (Promega) by adding 20 l/well MTS reagent
and incubating for 2 h at 37 °C before measuring the A490 using
a Spectramax Plus 382 plate reader. Real-time SYTOX Green
assays were performed by incubating cells with 1 M SYTOX
Green viability dye (Life Technologies) and measuring the
development of SYTOX Green-associated fluorescence over
72 h by time-resolved epifluorescence microscopy (excitation
at 440 – 480 nm, emission at 504 –544 nm) using an Incucyte
ZOOM epifluorescence live-cell imaging system (Essen Biosci-
ence; Nikon 4 objective). Data were analyzed using Incucyte
ZOOM software v2015A.
Statistical analysis
Data presented were analyzed by one-way analysis of vari-
ance with Tukey’s multiple comparison post-test or two-way
analysis of variance with Holm-Sidak multiple comparison
post-test using GraphPad Prism v6.00 for Windows.
Author contributions—P. C., R. A. B., and A. R. W. performed all
experiments and interpreted data. P. C. also contributed to author-
ing of the manuscript. M. R. W. was the coordinating author with
significant input from M. R., and M. R. W. and M. R. also designed
experiments and interpreted data.
Note added in proof—In the version of this article that was published
as a Paper in Press on July 14, 2017, Fig. 3A did not indicate the
borders between different sections of a gel. This error has now been
corrected and does not affect the results or conclusions of this work.
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